News Column

Supreme Hires Agoracom for Online Investor Relations

August 25, 2014



VANCOUVER, BRITISH COLUMBIA--(Marketwired - Aug. 25, 2014) - Supreme Pharmaceuticals Inc. (the "Company") (OTCBB:SPRWD)(CSE:SL) is pleased to report it has retained Agoracom, an online investor relations and marketing firm, to generate an awareness program.

The company has retained Agoracom for their online investor relation's initiatives. Pursuant to the terms of the Agreement, the company will issue common shares equal in value to $15,000 on each of the following dates: late August 15, 2014, December 15, 2014, March 15, 2015, and June 15, 2015.

Please find more information on Agoracom at www.agoracom.com.

In addition, after careful evaluation of medicinal marijuana opportunities in Arizona, the company has elected not to pursue them further and focus its attention on Canadian operations.

The company's current capital structure is as follows:

-- Common Shares Issued and Outstanding: 59,000,000 -- Warrants Outstanding: 2,506,000 at $0.25 and 3,100,000 at $0.50 -- Incentive Options Outstanding: 2,800,000 at $0.25



FORWARD-LOOKING INFORMATION

This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the acquisition of an MMPR license in respect to its Southern Okanagan facility, the timing on competition of the MMPR License conditions for its Southern Ontario facility and the start of production. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and such factors as the Company failing to acquire final MMPR licenses and put the same into production. This news release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995.

FOR FURTHER INFORMATION PLEASE CONTACT: Supreme Pharmaceuticals Inc. Investor Relations 430 - 580 Hornby Street, Vancouver BC, V6C 3B6 (604) 674-2191 info@supreme.cawww.supreme.ca Source: Supreme Pharmaceuticals Inc.


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: Marketwire (Canada)


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters